Acellular fraction from malignant effusions has cytotoxicity in breast cancer cells
- Javier Vargas-Villarrealc, d(Author),
- Marlid Cruz-Ramosf(Author),
- Alba Espino-Ojedab(Author),
- Hugo Gutierrez-Hermosillod, h(Author),
- Enrique Díaz DE LEON-GONZALEZd(Author),
- Ofelia Monsivais-Diazd(Author)
- ,
- bInstituto Tecnologico de Estudios Superiores de Monterrey,
- cUniversidad de Monterrey,
- dInstituto Mexicano del Seguro Social,
- eUniversidad Autonoma de Nuevo Leon,
- fUniversidad Autónoma de Madrid
Acceso abierto
Objetivos de Desarrollo Sostenible
- ODS 3: Salud y bienestar
Métricas de publicación
Métricas
PlumX, opens in new tab
Resumen
Malignant ascites (MA) and malignant pleural effusion (MPE) are frequently developed in patients with metastatic cancer; however, the biological properties of these fluids have not been clarified. The present study explored the biological role of a low molecular fraction derived from malignant effusions on the activation of peripheral blood mononuclear cells and on the proliferation of breast cancer cells and fibroblast 55x cells. A <10-kDa fraction from effusions of 41 oncological patients and 34 individuals without cancer was purified, and its potential role in inhibiting nitric oxide (NO) production on lipopolysaccharide (LPS)-stimulated peripheral blood mononuclear cells was explored, as well as its cytotoxicity on MCF-7 breast cancer cells and fibroblast 55x cells. A significant decrease in NO production was observed in the <10-kDa fraction from malignant effusions. In addition, the acellular fraction from MA decreased the viability of breast cancer cells without affecting human fibroblasts. These data support the presence of low molecular weight molecules in malignant samples with a specific role in inhibiting the defense mechanisms of peripheral blood mononuclear cells and decreasing the viability of breast cancer cells in vitro.
Información de Publicación
Tipo de resultado
Idioma original
EnglishNúmero de artículo
106Revista (Volumen, Número de Edición)
Molecular and Clinical Oncology (Volumen 14, Número 5)Hitos de publicación
- Published - 2021
Estado de publicación
ISSN
2049-9450ID de publicación externa
- Scopus: 85103860663
- PubMed: 33796293
